Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Tenax Therapeutics Inc
Healthcare
P/NCAV
0.11x
Ticker
TENX
Exchange
NASDAQ
Country
United States
Close
3.5 $
Mkt Cap
869575 $
EV
-8.4M $
NCAV Burn Rate
-524.8%
Current Ratio
3.26
Debt/Equity
0.06
EV/REV
N/Ax
EV/EBIT
1.0x
EV/FCF
1.4x
Dilution
87.1% p.A
Total Net Income
-153.7M $
Cheapness
100.0%
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company-s products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average